Amgen [AMGN] vs Bristol-Myers Squibb [BMY] Detailed Stock Comparison

Amgen Inc.

NASDAQ
Loading...

Bristol-Myers Squibb Company

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Amgen Inc. wins in 9 metrics, Bristol-Myers Squibb Company wins in 12 metrics, with 0 ties. Bristol-Myers Squibb Company appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Amgen Inc. Bristol-Myers Squibb Company Better
P/E Ratio (TTM) 24.22 17.06 Bristol-Myers Squibb Company
Price-to-Book Ratio 21.46 6.51 Bristol-Myers Squibb Company
Debt-to-Equity Ratio 640.28 254.98 Bristol-Myers Squibb Company
PEG Ratio 0.22 0.01 Bristol-Myers Squibb Company
EV/EBITDA 13.97 8.20 Bristol-Myers Squibb Company
Profit Margin (TTM) 20.98% 14.64% Amgen Inc.
Operating Margin (TTM) 30.55% 28.16% Amgen Inc.
EBITDA Margin (TTM) 30.55% 28.16% Amgen Inc.
Return on Equity 106.10% 40.44% Amgen Inc.
Return on Assets (TTM) 7.93% 10.29% Bristol-Myers Squibb Company
Free Cash Flow (TTM) $8.10B $12.85B Bristol-Myers Squibb Company
Dividend Yield 3.30% 5.82% Bristol-Myers Squibb Company
1-Year Return 20.32% 14.83% Amgen Inc.
Price-to-Sales Ratio (TTM) 5.06 2.50 Bristol-Myers Squibb Company
Enterprise Value $232.21B $156.74B Amgen Inc.
EV/Revenue Ratio 6.32 3.25 Bristol-Myers Squibb Company
Gross Profit Margin (TTM) 69.84% 67.23% Amgen Inc.
Revenue per Share (TTM) $68 $24 Amgen Inc.
Earnings per Share (Diluted) $14.24 $3.46 Amgen Inc.
Beta (Stock Volatility) 0.47 0.27 Bristol-Myers Squibb Company
Short % of Float 2.60% 1.54% Bristol-Myers Squibb Company

Amgen Inc. vs Bristol-Myers Squibb Company Stock Performance Analysis

Loading Price Chart...

AMGN
BMY

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Amgen Inc.-1.31%1.39%7.42%-4.29%7.75%6.99%
Bristol-Myers Squibb Company-1.56%1.21%-1.33%-5.81%3.59%5.20%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Amgen Inc.20.32%54.66%48.82%137.40%512.31%431.58%
Bristol-Myers Squibb Company14.83%-13.65%-14.05%-19.16%107.59%126.89%

Performance & Financial Health Analysis: Amgen Inc. vs Bristol-Myers Squibb Company

MetricAMGNBMY
Market Information
Market Cap i$187.93B$119.87B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i2,431,7538,535,002
90 Day Avg. Volume i2,596,29111,824,357
Last Close$350.53$56.24
52 Week Range$267.83 - $391.29$42.52 - $62.89
% from 52W High-10.42%-10.57%
All-Time High$391.29 (Mar 02, 2026)$81.44 (Nov 28, 2022)
% from All-Time High-10.42%-30.94%
Growth Metrics
Quarterly Revenue Growth0.09%0.01%
Quarterly Earnings Growth1.13%14.10%
Financial Health
Profit Margin (TTM) i0.21%0.15%
Operating Margin (TTM) i0.31%0.28%
Return on Equity (TTM) i1.06%0.40%
Debt to Equity (MRQ) i640.28254.98
Cash & Liquidity
Book Value per Share (MRQ)$16.07$9.07
Cash per Share (MRQ)$16.94$5.24
Operating Cash Flow (TTM) i$9.96B$14.16B
Levered Free Cash Flow (TTM) i$7.50B$11.15B
Dividends
Last 12-Month Dividend Yield i3.30%5.82%
Last 12-Month Dividend i$12.18$3.11

Valuation & Enterprise Metrics Analysis: Amgen Inc. vs Bristol-Myers Squibb Company

MetricAMGN (Apr 24, 2026)BMY (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i24.2217.06
Forward P/E i14.779.61
PEG Ratio i0.220.01
Price to Sales (TTM) i5.062.50
Price to Book (MRQ) i21.466.51
Market Capitalization
Market Capitalization i$187.93B$119.87B
Enterprise Value i$232.21B$156.74B
Enterprise Value Metrics
Enterprise to Revenue i6.323.25
Enterprise to EBITDA i13.978.20
Risk & Other Metrics
Beta i0.470.27
Book Value per Share (MRQ) i$16.07$9.07

Financial Statements Comparison: Amgen Inc. vs Bristol-Myers Squibb Company

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricAMGN (2025)BMY (2025)
Revenue/Sales i36.75B48.20B
Cost of Goods Sold i12.04B13.94B
COGS % of Revenue i32.8%28.9%
Gross Profit i24.71B34.26B
Gross Margin i67.2%71.1%
Research & Development i7.27B9.95B
Operating Income (EBIT) i9.08B13.72B
Operating Margin i24.7%28.5%
EBITDA i16.90B19.95B
EBITDA Margin i46.0%41.4%
Pre-Tax Income i8.98B9.33B
Pre-Tax Income % of Revenue i24.4%19.4%
Income Tax i1.27B2.27B
Income Tax % of Revenue i3.4%4.7%
Net Income (Profit) i7.71B7.06B
Profit Margin i21.0%14.6%

Balance Sheet & Liquidity Metrics

MetricAMGN (2025)BMY (2025)
Cash & Equivalents i9.13B10.21B
Total Current Assets i29.06B29.39B
Total Current Assets % of Revenue i79.1%61.0%
Total Current Liabilities i25.49B23.42B
Total Current Liabilities % of Revenue i69.4%48.6%
Long-Term Debt i50.01B44.68B
Long-Term Debt % of Revenue i136.1%92.7%
Total Shareholders Equity i8.66B18.51B
Retained Earnings i-25.11B16.90B
Retained Earnings % of Revenue i-68.3%35.1%
Property, Plant & Equipment i5.22B1.58B

Cash Flow Statement Comparison

MetricAMGN (2025)BMY (2025)
Operating Cash Flow i10.51B14.51B
Operating Cash Flow % of Revenue i28.6%30.1%
Capital Expenditures i-1.86BN/A
Free Cash Flow i8.10B12.85B
FCF Margin i22.0%26.7%
Debt Repayment i-5.00B-10.94B
Common Stock Repurchase i00

Short Interest & Institutional Ownership Analysis

MetricAMGNBMY
Shares Short i13.98M31.50M
Short Ratio i5.432.29
Short % of Float i2.60%1.54%
Shares Outstanding i538.80M2.04B
Float Shares i537.62M2.03B
% Held by Insiders i0.22%0.09%
% Held by Institutions i85.36%83.86%
% Held by Public i14.42%16.05%

Dividend Analysis & Yield Comparison: Amgen Inc. vs Bristol-Myers Squibb Company

MetricAMGNBMY
Last 12-Month Dividend i$12.18$3.11
Last 12-Month Dividend Yield i3.30%5.82%
3-Year Avg Annual Dividend i$9.98$2.60
3-Year Avg Dividend Yield i0.77%1.13%
3-Year Total Dividends i$29.95$7.79
Ex-Dividend DateMay 15, 2026Jan 02, 2026